Ignite Creation Date:
2024-05-06 @ 2:10 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01985061
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2018-07-13
First Post:
2013-10-31
Brief Title:
Evaluation of 3 Different Doses of IV Busulfan
Sponsor:
Institut Paoli-Calmettes
Organization:
Institut Paoli-Calmettes
Study Overview
Official Title:
Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation SCT From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AAA
Brief Summary:
Albeit the safety of the stem cell transplantation procedure has been greatly improved further refining the intensity of the conditioning is an important issue to explore especially in patients with poor prognosis the goal being to maintain the very favorable safety profile and improve the disease control This is the goal our prospective trial we aim to prospectively evaluate in a prospective multicenter trial the efficacy of different conditioning regimens in patients with high-risk myeloid malignancies
The study is a phase II trial randomizing patients between a prospective active control arm BX2 and two experimental arms BX3 and BX4 A standard group was kept in this clinical trial in order to avoid the limitations induced by the comparison with historical controls in the context of continuously improving practice Each experimental arm will be conducted in parallel according to a standard phase II trial design
In addition this trial will associate four ancillary studies to the main clinical objective 1 a prospective assessment of the quality of life of the patients over a period of 2 years 2 an analysis of the cost effectiveness of the procedure assessed over a period of 2 years 3 an observational busulfan pharmacokinetic study 4 a busulfan pharmacogenomic study
The study is a phase II trial randomizing patients between a prospective active control arm BX2 and two experimental arms BX3 and BX4 A standard group was kept in this clinical trial in order to avoid the limitations induced by the comparison with historical controls in the context of continuously improving practice Each experimental arm will be conducted in parallel according to a standard phase II trial design
In addition this trial will associate four ancillary studies to the main clinical objective 1 a prospective assessment of the quality of life of the patients over a period of 2 years 2 an analysis of the cost effectiveness of the procedure assessed over a period of 2 years 3 an observational busulfan pharmacokinetic study 4 a busulfan pharmacogenomic study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None